| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
32,214 |
30,671 |
$3.50M |
| 41899 |
Unlisted procedure, dentoalveolar structures |
2,184 |
2,086 |
$2.17M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
17,589 |
16,606 |
$2.16M |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
7,087 |
6,792 |
$1.22M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
6,706 |
6,320 |
$770K |
| 71046 |
Radiologic examination, chest; 2 views |
6,176 |
5,959 |
$462K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
5,500 |
5,295 |
$385K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,539 |
1,454 |
$313K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
283 |
268 |
$260K |
| 71045 |
Radiologic examination, chest; single view |
4,050 |
3,803 |
$233K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
6,789 |
6,363 |
$188K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
5,357 |
4,943 |
$186K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
6,218 |
5,922 |
$175K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
19,683 |
17,777 |
$140K |
| 0225U |
|
354 |
337 |
$140K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,535 |
1,408 |
$130K |
| 80053 |
Comprehensive metabolic panel |
15,262 |
13,856 |
$122K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,402 |
1,240 |
$94K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,415 |
1,101 |
$93K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,846 |
1,664 |
$88K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,217 |
1,984 |
$79K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,844 |
1,762 |
$73K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,844 |
2,785 |
$73K |
| 81025 |
|
5,871 |
5,516 |
$50K |
| 84484 |
|
4,226 |
3,782 |
$37K |
| J3490 |
Unclassified drugs |
3,121 |
2,735 |
$35K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
753 |
694 |
$34K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,527 |
1,391 |
$29K |
| 81001 |
|
8,550 |
8,126 |
$28K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
802 |
750 |
$22K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
27 |
26 |
$21K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
551 |
486 |
$21K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
726 |
630 |
$19K |
| 36410 |
|
717 |
431 |
$19K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,453 |
2,338 |
$16K |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
92 |
87 |
$14K |
| 81003 |
|
5,050 |
4,738 |
$14K |
| 83690 |
|
1,662 |
1,556 |
$13K |
| 87088 |
|
1,324 |
1,247 |
$11K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,365 |
1,146 |
$9K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,103 |
2,013 |
$9K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
339 |
314 |
$9K |
| 87430 |
|
626 |
615 |
$8K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,804 |
2,657 |
$8K |
| 83735 |
|
1,384 |
1,282 |
$8K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
2,188 |
2,092 |
$7K |
| 87807 |
|
489 |
475 |
$6K |
| 84443 |
Thyroid stimulating hormone (TSH) |
379 |
353 |
$5K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
178 |
172 |
$5K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
178 |
172 |
$5K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,106 |
1,027 |
$5K |
| 85610 |
|
1,435 |
1,368 |
$4K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
604 |
592 |
$4K |
| A4217 |
Sterile water/saline, 500 ml |
332 |
200 |
$4K |
| 83880 |
|
163 |
156 |
$4K |
| 86141 |
|
229 |
218 |
$3K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
121 |
115 |
$3K |
| 87077 |
|
294 |
282 |
$3K |
| 87070 |
|
246 |
240 |
$2K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
12 |
12 |
$2K |
| 86850 |
|
186 |
172 |
$2K |
| 87081 |
|
331 |
325 |
$2K |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
24 |
24 |
$2K |
| 85027 |
|
229 |
217 |
$2K |
| 86592 |
|
353 |
327 |
$2K |
| 83605 |
|
145 |
133 |
$2K |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
14 |
14 |
$1K |
| 86762 |
|
92 |
87 |
$1K |
| 86787 |
|
92 |
87 |
$1K |
| 87340 |
|
113 |
108 |
$1K |
| 82962 |
|
381 |
288 |
$976.05 |
| 86901 |
|
190 |
176 |
$972.02 |
| 86900 |
|
190 |
176 |
$972.02 |
| J2704 |
Injection, propofol, 10 mg |
264 |
254 |
$936.72 |
| 94664 |
|
59 |
56 |
$879.59 |
| 87040 |
|
65 |
59 |
$860.98 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
173 |
160 |
$789.66 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
75 |
74 |
$785.85 |
| 82077 |
|
160 |
143 |
$678.24 |
| 85379 |
|
69 |
61 |
$627.50 |
| J3535 |
Drug administered through a metered dose inhaler |
13 |
13 |
$609.78 |
| 85730 |
|
145 |
131 |
$605.47 |
| 87186 |
|
72 |
68 |
$600.08 |
| 85660 |
|
93 |
88 |
$529.76 |
| 74018 |
|
13 |
12 |
$360.36 |
| 82728 |
|
26 |
24 |
$291.94 |
| 84466 |
|
26 |
24 |
$250.09 |
| 82550 |
|
56 |
53 |
$242.12 |
| 84702 |
|
15 |
14 |
$163.50 |
| 83540 |
|
26 |
24 |
$127.04 |
| 86140 |
|
26 |
26 |
$103.20 |
| G1010 |
Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program |
588 |
459 |
$61.96 |
| 87210 |
|
12 |
12 |
$39.92 |